News

Select Year

• February 10, 2026

  FYR Bio Appoints Barbara K. Zehentner, MBA, Ph.D., HCLD (ABB), as Chief Operating Officer

• December 1, 2025

  Poster | SNO 2025 | Sex-associated Biomarker Signatures in Malignant Glioma: Insights from a Proteomics Study

• November 19, 2025

  FYR Bio and NuvOx Therapeutics Awarded NCI Direct-to-Phase II SBIR Grant to Advance Liquid-Biopsy Collaboration in Phase IIb Glioblastoma Trial

• October 9, 2025

  FYR Integrates CIQ Fuzzball to Scale AI-Enabled Multiomic Platform and Accelerate Breakthroughs in Precision Medicine

• September 24, 2025

  FYR Closes $8 Million Financing to Advance Blood-Based Biomarkers Across Oncology and Neuroscience